{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T14:28:56Z","timestamp":1724077736765},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T00:00:00Z","timestamp":1448236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s00115-015-0021-9","type":"journal-article","created":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T11:56:16Z","timestamp":1448279776000},"page":"719-723","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chancen und Kontroversen von Depotantipsychotika in der Behandlung von Patienten mit Schizophrenie"],"prefix":"10.1007","volume":"87","author":[{"given":"S.","family":"Breit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Hasler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,23]]},"reference":[{"issue":"14","key":"21_CR1","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1517\/14656566.2010.499125","volume":"11","author":"O Agid","year":"2010","unstructured":"Agid O et al (2010) Long acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother 11(14):2301\u20132317","journal-title":"Expert Opin Pharmacother"},{"key":"21_CR2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-244X-10-2","volume":"10","author":"H Ascher-Savanum","year":"2010","unstructured":"Ascher-Savanum H et al (2010) The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 10:2","journal-title":"BMC Psychiatry"},{"issue":"3","key":"21_CR3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4088\/JCP.v67n0317","volume":"67","author":"H Ascher-Svanum","year":"2006","unstructured":"Ascher-Svanum H et al (2006) Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 67(3):453\u2013460","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"21_CR4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1742-1241.2009.02240.x","volume":"64","author":"L Citrome","year":"2010","unstructured":"Citrome L (2010) Paliperidone palmitate \u2013 review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract 64(2):216\u2013239","journal-title":"Int J Clin Pract"},{"key":"21_CR5","first-page":"CD001164","volume":"2","author":"E Coutinho","year":"2000","unstructured":"Coutinho E, Fenton M, Quraishi S (2000) Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev 2:CD001164","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"21_CR6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/2045125314542098","volume":"4","author":"AK Das","year":"2014","unstructured":"Das AK et al (2014) A qualitative study of the attitudes of patients in an early intervention service towards\u00a0antipsychotic\u00a0long-acting injections. Ther Adv Psychopharmacol 4(5):179\u2013185","journal-title":"Ther Adv Psychopharmacol"},{"issue":"10","key":"21_CR7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-244X-10-43","volume":"10","author":"HC Detke","year":"2010","unstructured":"Detke HC et al (2010) Post-injection delirium\/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 10(10):43","journal-title":"BMC Psychiatry"},{"key":"21_CR8","volume-title":"Psychotherapie und Nervenheilkunde (DGPPN), S3 Behandlungsleitlinie Schizophrenie","author":"Deutsche Gesellschaft f\u00fcr Psychiatrie","year":"2006","unstructured":"Deutsche Gesellschaft f\u00fcr Psychiatrie (2006) Psychotherapie und Nervenheilkunde (DGPPN), S3 Behandlungsleitlinie Schizophrenie. Deutsche Gesellschaft f\u00fcr Psychiatrie, Berlin"},{"issue":"6","key":"21_CR9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/YIC.0b013e32830c2042","volume":"23","author":"R Emsley","year":"2008","unstructured":"Emsley R et al (2008) Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 23(6):325\u2013331","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"21_CR10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2012.02.030","volume":"138","author":"R Emsley","year":"2012","unstructured":"Emsley R et al (2012) Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr Res 138(1):29\u201334","journal-title":"Schizophr Res"},{"issue":"4","key":"21_CR11","first-page":"171","volume":"28","author":"WW Fleischhacker","year":"2013","unstructured":"Fleischhacker WW et al (2013) Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Int Clin Psychopharmacol 28(4):171\u2013176","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"21_CR12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/YIC.0b013e32835b091f","volume":"28","author":"P Fusar-Poli","year":"2013","unstructured":"Fusar-Poli P, Kempton MJ, Rosenheck RA (2013) Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol 28(2):57\u201366","journal-title":"Int Clin Psychopharmacol"},{"issue":"10","key":"21_CR13","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.euroneuro.2011.08.008","volume":"21","author":"A Gustavsson","year":"2011","unstructured":"Gustavsson A et al (2011) Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21(10):718\u2013779","journal-title":"Eur Neuropsychopharmacol"},{"issue":"9","key":"21_CR14","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.euroneuro.2014.06.015","volume":"24","author":"J Hamann","year":"2014","unstructured":"Hamann J et al (2014) Checking the plausibility of psychiatrists\u2019 arguments for not prescribing depot medication. Eur Neuropsychopharmacol 24(9):1506\u20131510","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"21_CR15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1192\/bjp.187.1.9","volume":"187","author":"K Hawton","year":"2005","unstructured":"Hawton K et al (2005) Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 187(1):9\u201320","journal-title":"Br J Psychiatry"},{"issue":"12","key":"21_CR16","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.4088\/JCP.v67n1216","volume":"67","author":"S Heres","year":"2006","unstructured":"Heres S et al (2006) Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 67(12):1948\u20131953","journal-title":"J Clin Psychiatry"},{"issue":"5 Suppl 1","key":"21_CR17","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1177\/088740341305805s03","volume":"58","author":"S Iyer","year":"2013","unstructured":"Iyer S et al (2013) A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part\u00a0I-patient perspectives. Can J Psychiatry 58(5 Suppl 1):14S\u201322S","journal-title":"Can J Psychiatry"},{"issue":"5 Suppl 1","key":"21_CR18","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1177\/088740341305805s04","volume":"58","author":"S Iyer","year":"2013","unstructured":"Iyer S et al (2013) A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part\u00a0II-physician perspectives. Can J Psychiatry 58(5 Suppl 1):23S\u201329S","journal-title":"Can J Psychiatry"},{"issue":"5","key":"21_CR19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4088\/JCP.11m07530","volume":"73","author":"JM Kane","year":"2012","unstructured":"Kane JM et al (2012) Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 73(5):617\u2013624","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"21_CR20","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3111\/13696998.2013.804411","volume":"16","author":"JM Kane","year":"2013","unstructured":"Kane JM et al (2013) Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. J Med Econ 16(7):917\u2013925","journal-title":"J Med Econ"},{"issue":"9","key":"21_CR21","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00115-013-3842-4","volume":"85","author":"S Kohler","year":"2013","unstructured":"Kohler S, Heinz A, Sterzer P (2013) Long-acting injectable antipsychotics : overview and advice for daily routine care. Nervenarzt 85(9):1067\u20131074","journal-title":"Nervenarzt"},{"issue":"11","key":"21_CR22","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0006-3223(01)01303-8","volume":"50","author":"JA Lieberman","year":"2001","unstructured":"Lieberman JA et al (2001) The early stages of schizophrenia: speculations on pathogenesis, pathophysiology and therapeutic approaches. Biol Psychiatry 50(11):884\u2013897","journal-title":"Biol Psychiatry"},{"issue":"19","key":"21_CR23","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1001\/jama.2014.4310","volume":"311","author":"JP McEvoy","year":"2014","unstructured":"McEvoy JP et al (2014) Effectiveness of paliperidone palmitate vs. haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA 311(19):1978\u20131987","journal-title":"JAMA"},{"key":"21_CR24","volume-title":"Psychosis and Schizophrenia in Adults: Treatment and Management. Clinical guideline CG178","author":"National Institute for Health and Care Excellence","year":"2014","unstructured":"National Institute for Health and Care Excellence (2014) Psychosis and Schizophrenia in Adults: Treatment and Management. Clinical guideline CG178. National Institute for Health and Care Excellence, London"},{"key":"21_CR25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1034\/j.1600-0447.2000.00016.x","volume":"407","author":"M Oehl","year":"2000","unstructured":"Oehl M, Hummer M, Fleischhacker WW (2000) Compliance with antipsychotic treatment. Acta Psychiatr Scand Suppl 407:83\u201386","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"4","key":"21_CR26","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1192\/bjp.bp.109.067694","volume":"196","author":"DC Owens","year":"2010","unstructured":"Owens DC et al (2010) Duration of untreated illness and outcome in schizophrenia: test of predictions in relation to relapse risk. Br J Psychiatry 196(4):296\u2013301","journal-title":"Br J Psychiatry"},{"issue":"1","key":"21_CR27","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","volume":"35","author":"G Pandina","year":"2011","unstructured":"Pandina G et al (2011) A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35(1):218\u2013226","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"21_CR28","first-page":"9","volume":"3","author":"X Peng","year":"2011","unstructured":"Peng X et al (2011) Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res 3:9\u201314","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"21_CR29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1744-859X-11-21","volume":"11","author":"D Primavera","year":"2012","unstructured":"Primavera D et al (2012) Does duration of untreated psychosis predict very long term outcome of schizophrenic disorders? Results of a retrospective study. Ann Gen Psychiatry 11(1):21","journal-title":"Ann Gen Psychiatry"},{"issue":"3","key":"21_CR30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","volume":"56","author":"D Robinson","year":"1999","unstructured":"Robinson D et al (1999) Predictors of treatment response from a first episode of schizophrenia or schizoaffactive disorder. Arch Gen Psychiatry 56(3):241\u2013247","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"21_CR31","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0269881108100774","volume":"24","author":"P Shajahan","year":"2010","unstructured":"Shajahan P, Taylor M (2010) The uses and outcomes of quetiapine in depressive and bipolar mood disorders in clinical practice. J Psychopharmacol 24(4):565\u2013572","journal-title":"J Psychopharmacol"},{"issue":"4","key":"21_CR32","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1176\/ps.2007.58.4.482","volume":"58","author":"L Shi","year":"2007","unstructured":"Shi L et al (2007) Characteristics and use patterns of patients taking first generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv 58(4):482\u2013488","journal-title":"Psychiatr Serv"},{"issue":"6","key":"21_CR33","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","volume":"168","author":"J Tiihonen","year":"2011","unstructured":"Tiihonen J et al (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168(6):603\u2013609","journal-title":"Am J Psychiatry"},{"issue":"1-3","key":"21_CR34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.schres.2013.11.042","volume":"153","author":"PJ Weiden","year":"2014","unstructured":"Weiden PJ et al (2014) A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophr Res 153(1-3):160\u2013168","journal-title":"Schizophr Res"},{"issue":"10","key":"21_CR35","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4088\/JCP.09m05284yel","volume":"70","author":"PJ Weiden","year":"2009","unstructured":"Weiden PJ et al (2009) A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry 70(10):1397\u20131406","journal-title":"J Clin Psychiatry"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-015-0021-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-015-0021-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-015-0021-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T05:15:02Z","timestamp":1558588502000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-015-0021-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,23]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["21"],"URL":"https:\/\/doi.org\/10.1007\/s00115-015-0021-9","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,23]]}}}